GlaxoSmithKline plc
(the 'Company')
Transfer of Treasury Shares
On 10 February 2020, the Company transferred 25,800,000 ordinary shares of 25 pence each ("Ordinary Shares") that were held by the Company in treasury ("Treasury Shares") to JPMorgan Chase Bank, N.A. the depositary of the Company's American depositary receipts ("ADR") programme, to procure the issuance and transfer of 12,900,000 ADRs of the Company to the GlaxoSmithKline (US) Trust (the "Trust") to be used to satisfy awards granted under the Company's Deferred Annual Bonus Plan, Performance Share Plan and Share Value Plan. The consideration received from the trustee of $43.95 per ADR, representing $21.975 per Ordinary Share, was funded by a contribution to the Trust from GlaxoSmithKline LLC.
Following the transfer, the Company's issued share capital consisted of 5,384,119,172 Ordinary Shares, of which 367,705,950 were held as Treasury Shares.
Therefore, the total number of voting rights in the Company is 5,016,413,222. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.
V A Whyte
Company Secretary
11 February 2020
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
